Glatiramer acetate
Glatiramer acetate is a pharmaceutical drug with 27 clinical trials. Currently 2 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
6
Mid Stage
14
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
68.2%
15 of 22 finished
31.8%
7 ended early
2
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Clinical Trials (27)
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
Safety of New Formulation of Glatiramer Acetate
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
Treatment of Multiple Sclerosis With Copaxone and Albuterol
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27